Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to ongoing clinical development. They did not provide specific guidance for the upcoming quarters.
Management did not provide specific guidance for future quarters.
The focus remains on advancing clinical programs and partnerships.
IDEAYA Biosciences I's earnings report showed a significant stock price increase of 47.44%, indicating strong investor interest. The lack of revenue data and specific guidance suggests uncertainty, but the market reacted positively, likely due to the company's ongoing clinical initiatives. Investors may be optimistic about future developments despite the negative EPS.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UGI CORP NEW
Nov 11, 2019